Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years

NCT01827605 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.

NCT NCT01827605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01827605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years
Lead sponsor
Fondazione Italiana Linfomi - ETS
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2012
Completion date
January 31, 2024
Enrollment
159 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed follicular lymphoma